Greenwich LifeSciences, Inc. Board of Directors

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Mr. Snehal S. Patel

Mr. Snehal S. Patel

CEO, CFO & Director

Mr. Eric Rothe

Mr. Eric Rothe

Founder & Independent Director

Dr. Frank Joseph Daugherty M.D.

Dr. Frank Joseph Daugherty M.D.

Chief Medical Officer & Director

Dr. Jaye L. Thompson Ph.D.

Dr. Jaye L. Thompson Ph.D.

Vice President Clinical & Regulatory Affairs

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.